Visit the Regional Educational Programs for more information about the following upcoming programming:

Member Institution Programs:

• JAX Clinical Education & MCGI's Interpreting Biomarker Testing for Genetic Counselors

Industry Supported Programs:

Nonprofit Sponsored Programs:

• September 2025 - March 2026 - American Cancer Society's Building Pathways to Fertility Preservation in Cancer (monthly virtual sessions)

https://asco.quorum.us/campaign/56411/

Enjoy this wonderful interview with 3 of NNECOS' founding members!

Latest FDA Approval

• February 26 - FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer
• February 24 - FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation
• February 10 - FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
• January 27 - FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
• December 17 - FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection
• December 17 - FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer
• December 15 - FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer
• December 12 - FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer
• December 4 - FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma
• December 3 - FDA grants traditional approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma
• November 25 - FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma
• November 21 - FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer
• November 19 - FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas
• November 19 - FDA grants traditional approval to daratumumab and hyaluronidase-fihj for newly diagnosed light chain amyloidosis
• November 19 - FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
• November 19 - FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer
• November 18 - FDA approves epcoritamab-bysp for follicular lymphoma indications
• November 13 - FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation
• November 6 - FDA approves daratumumab and hyaluronidase-fihj for high-risk smoldering multiple myeloma

Package/Label Updates

• Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency
  

Code Updates

• Effective January 1, 2026, the following C-code can be used for administrative and billing purposes specific to LYNOZYFIC:

  C9307 – Injection, linvoseltamab-gcpt, 1 mg

• Claim Issue Reported 1/8/25 impacting Part B providers in Jurisdiction JK and Jurisdiction J6 - Claims with healthcare common procedure coding system (HCPCS) G2211 with date of service (DOS) 1/1/2024-9/30/2024.

• Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection:
  

Other Updates